EPO and anemia (phenotype): Whereas treatment of humans or mice with PT2385 or PT2399/belzutifan caused anemia due to inhibition of erythropoietin expression (140, 165, 166), treatment of mice with 32-134D did not affect plasma erythropoietin levels or red blood cell indices and had no effect on appearance, behavior, or body weight (177).